Evidence map›Paper›PMID 29878001›Full record

ArticleThe Analyst2018

Nanoscale partitioning of paclitaxel in hybrid lipid-polymer membranes.

Mohit Tuteja, Minjee Kang, Cecilia Leal, Andrea Centrone

Abstract read
In one paragraph

Article in The Analyst, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. What Do Different Modes of AFM-IR Mean for Measuring Soft Matter Surfaces?Langmuir : the ACS journal of surfaces and colloids · 2023
    Review
  6. Review
  7. Communications chemistry · 2023
    Article
  8. Article
  9. Nanostructure-enhanced infrared spectroscopy.Nanophotonics (Berlin, Germany) · 2022
    Review
  10. Polymer-Lipid Hybrid Materials.Chemical reviews · 2021
    Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. High-Nanophotonics (Berlin, Germany) · 2020
    Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Mohit TutejaCenter for Nanoscale Science and Technology, National Institute of Standards and Technology, Gaithersburg, MD 20899, USA. andrea.centrone@nist.gov.
Minjee Kang
Cecilia Leal
Andrea Centrone
National Institute of Standards and Technology · USUniversity of Illinois Urbana-Champaign · US

Funding

A New Paradigm in Nanomedicine: can structural interiors of nanoparticles regulate cellular delivery?DP2EB024377 · NIBIB · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI LEAL, CECILIA MARIA · 2016 to 2016
$2.3M
Intramural NIST DOC 9999-NISTNIBIB NIH HHS DP2 EB024377
6 · The paper itself

Abstract

Paclitaxel is a powerful drug against restenosis and many forms of cancer. However, its clinical application hinges on the ability to achieve suitable stabilized drug concentrations in an aqueous suspension while hindering drug crystallization. To engineer such formulations, it is imperative to understand paclitaxel's partitioning and crystallization within the carrier matrix. Lipid-polymer hybrid films have been recently shown to accommodate large paclitaxel loads and suppress crystallization. Additionally, such hybrid materials promote synergistic drug release compared to the pure constituents. Here, we leverage the composition sensitive photo-thermal induced resonance (PTIR) technique to study paclitaxel partitioning within hybrid films at the nanoscale. PTIR data reveal that paclitaxel nano-crystals segregate from lipid-only films but are well dispersed in polymer-only films. Remarkably, lipid-polymer hybrid films show enhanced partitioning of paclitaxel at the lipid-polymer phase boundaries, but still stifle crystallization, thus paving the way towards compositional and microstructural engineering of small-drug delivery systems.

Indexed as

Drug Delivery SystemsCrystallizationLipidsPaclitaxelPolymersLipidsPaclitaxelPolymers

Identifiers

PMID29878001
PMCPMC6215448
OpenAlexW2807569347

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.